KPRX — Kiora Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Kiora Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview
Kiora Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Kiora Pharmaceuticals Says Brian Strem Appointed Principal Financial Officer
Kiora Pharmaceuticals Inc expected to post a loss of 23cents a share - Earnings Preview
Brief: Kiora Pharmaceuticals Inc Appointed Michael Meluzio As Company's Principal Financial Officer
Brief: Kiora Pharmaceuticals Inc - On Feb 9, Sarah Romano, Notified Co She Will Resign As Chief Financial Officer Effective As Of February 25, 2022
Brief: Stephen From Resigns As Executive Chairman Of Kiora Pharmaceuticals
Brief: Kiora Pharmaceuticals Reports Kio-101 Safe And Tolerable Topline Data Supports Advancing Kio-101 To Phase 2 Study In Patients With Dry Eye Disease
Kiora Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Kiora Pharmaceuticals Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: EyeGate Is Now Kiora Pharmaceuticals
Brief: EyeGate Pharma Appoints Eric Daniels As Chief Development Officer And Closes Acquisition Of Bayon Therapeutics
Brief: EyeGate Pharma Completes Target Enrollment In Phase 2 Proof-Of-Concept Study To Evaluate PP-001 For Treatment Of Ocular Surface Inflammation
U.S. RESEARCH ROUNDUP-ACV Auctions, Blackberry, Veoneer
EyeGate Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: EyeGate Pharma Reports Q2 2021 Financial Results
EyeGate Pharmaceuticals Inc expected to post a loss of 42 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Katapult, PharmaCyte Biotech, Fulcrum Therapeutics
EyeGate Pharma slumps on share offering